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ABSTRACT  17 
Background Technological progress has enabled the provision of personalised feedback 18 
across multiple dimensions of physical activity that are important for health. Whether this 19 
multidimensional approach supports physical activity behaviour change has not yet been 20 
examined.  Our objective was to examine the effectiveness of a novel digital system and app 21 
that provided multidimensional physical activity feedback combined with health trainer 22 
support in primary care patients identified as at risk of chronic disease. 23 
 24 
Methods MIPACT was a parallel-group, randomised controlled trial that recruited patients 25 
at medium (≥10 and <20%) or high (≥20%) risk of cardiovascular disease and/or type II 26 
diabetes from six primary care practices in the United Kingdom. Intervention group 27 
participants (n=120) received personal multidimensional physical activity feedback using a 28 
customised digital system and web-app for 3 months plus five health trainer-led sessions. All 29 
participants received standardised information regarding physical activity. Control group 30 
participants (n=84) received no further intervention. The primary outcome was device-based 31 
assessment of physical activity at 12 months. 32 
 33 
Results Mean intervention effects were: moderate-vigorous physical activity:  -1.1 (95% CI, -34 
17.9 to 15.7) min/day; moderate-vigorous physical activity in ≥10-minute bouts: 0.2 (-14.2 to 35 
14.6) min/day; Physical Activity Level (PAL): 0.00 (-0.036 to 0.054); vigorous physical 36 
activity: 1.8 (-0.8 to 4.2) min/day; and sedentary time: 10 (-19.3 to 39.3) min/day.  For all of 37 
these outcomes, the results showed that the groups were practically equivalent and 38 
statistically ruled out meaningful positive or negative effects (>minimum clinically important 39 
difference, MCID). However, there was profound physical activity multidimensionality, and 40 
only a small proportion (5%) of patients had consistently low physical activity across all 41 
dimensions.  42 
 43 
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Conclusion In patients at risk of cardiovascular disease and/or type II diabetes, MIPACT did 44 
not increase mean physical activity. Using a sophisticated multidimensional digital approach 45 
revealed enormous heterogeneity in baseline physical activity in primary care patients, and 46 
practitioners may need to screen for low physical activity across dimensions rather than rely 47 
on disease-risk algorithms that are heavily influenced by age. 48 
 49 
Trial Registration This trial is registered with the ISRCTN registry (ISRCTN18008011; 50 
registration date 31 July 2013). 51 
 52 
Keywords: Physical activity, Technology, Primary care, Cardiovascular disease, Diabetes, 53 
Lifestyle intervention  54 
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INTRODUCTION 55 
Low physical activity is a major public health problem and an important independent risk 56 
factor for chronic diseases such as cardiovascular disease (CVD) and type II diabetes [1]. 57 
Primary care provides a potential route to change physical activity in patients at risk of 58 
chronic disease. In the United Kingdom, National Health Service (NHS) Health Checks 59 
screen for at-risk adults and include brief advice on increasing physical activity [2]. However, 60 
past attempts to change physical activity in primary care have had only limited success [3]. 61 
Identifying strategies to increase physical activity in high-risk individuals in primary care 62 
settings remains a priority. 63 
 64 
New digital technologies have the potential to transform the way in which physical activity is 65 
integrated into healthcare and used to target individuals at risk of long-term conditions [4]. 66 
Technology-assisted approaches can support more sophisticated, flexible and personalised 67 
delivery models [4-6] and can integrate key behavioural strategies associated with greater 68 
intervention effectiveness for modifying physical activity, including self-monitoring and 69 
feedback on behaviour [7, 8]. Indeed, a recent systematic review and meta-analysis called 70 
for future interventions aiming to promote longer term physical activity to specifically 71 
consider using personalised feedback as a behaviour change technique in order to enhance 72 
intervention effects [9]. 73 
 74 
Emerging evidence suggests that the health benefits of physical activity can be achieved in 75 
a variety of ways, and multiple dimensions (aspects) of physical activity are important for 76 
health promotion and disease prevention [10, 11]. Our past research shows that many 77 
people misjudge their physical activity status because they do not have access to accurate 78 
personalised information [12, 13]. We developed technology to capture multiple dimensions 79 
of physical activity and thus improve the depth and quality of feedback provided to 80 
individuals [14]. In addition to offering a more complete and integrated view of personal 81 
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physical activity, a multidimensional approach potentially offers more behavioural options 82 
that can be tailored to an individual’s needs and preferences [10]. 83 
 84 
In the Multidimensional Individualised Physical ACTivity (MIPACT) study, we conducted a 85 
randomised controlled trial to examine whether technology-enabled feedback about 86 
personalised multidimensional physical activity combined with support from health trainers 87 
increased physical activity in patients at risk of cardiovascular disease and/or type II 88 
diabetes, recruited from primary care. This trial was funded by the National Prevention 89 
Research Initiative (NPRI) – a partnership of research councils, government, and medical 90 
charities in the United Kingdom prioritising disease prevention. Prior qualitative feedback 91 
from at-risk patients was used to inform the design of physical activity visualisations, the 92 
development of an accompanying web-based app for communicating novel multidimensional 93 
physical activity feedback and the inclusion of health trainer support in the present trial [12, 94 
13].  95 
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METHODS 96 
Study design 97 
The MIPACT study was a parallel group, single blind, randomised clinical trial enrolling 204 98 
patients identified as being at risk of cardiovascular disease and/or type II diabetes, and 99 
consisted of a 3-month intervention period with follow-up at 3 and 12 months (primary 100 
timepoint). Ethics approval was obtained from the National Health Service (NHS) South 101 
West Research Ethics Committee (13/SW/0179). All patients provided written informed 102 
consent. The trial was registered on the ISRCTN registry on 31 July 2013 103 
(ISRCTN18008011). A full protocol detailing trial methods has been published previously 104 
[15]. Data were collected and reported according to CONSORT guidelines (Additional file 1). 105 
 106 
Participants 107 
Patients were recruited from six general medical practices in the South West of the United 108 
Kingdom between May 2014 and June 2015. Potential participants were approached via a 109 
letter from their General Practitioner. Eligible patients were men and women aged 40-70 110 
years treated in primary care and with medium (≥10 and <20%) or high (≥20%) risk of 111 
cardiovascular disease and/or type II diabetes. Risk scores were based on QRISK and 112 
QDiabetes prediction algorithms [16, 17] using clinical data. As our focus was on prevention, 113 
patients with existing coronary heart disease, heart failure, peripheral arterial disease, 114 
stroke, chronic kidney disease and diabetes mellitus were excluded. Individuals unable to 115 
increase physical activity or highly physically active individuals (a PAL – the ratio of total 116 
energy expenditure to basal metabolic rate – greater than 2.0) were also excluded. 117 
 118 
Randomisation and allocation 119 
Eligible patients were allocated to one of two groups using an unequal allocation ratio 120 
(intervention: control) of 2:1, primarily to increase our experience with and amount of 121 
information on the new intervention with respect to delivery, receipt, and enaction [18]. 122 
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Participants were allocated remotely by the trial statistician via concealed minimisation [19], 123 
providing balance across the trial arms for sex (male/female), general practice (1-5), risk 124 
(both cardiovascular disease and type II diabetes; medium/high) and baseline PAL (<1.75 or 125 
>1.75). Individual patients were the unit of randomisation, but there was no threat of 126 
contamination within a practice given that the intervention was personalised. Researchers 127 
assessing the primary outcomes were blinded to the allocation of participants.  128 
 129 
Intervention 130 
The MIPACT intervention was a complex ‘treatment package’ developed in line with Medical 131 
Research Council guidelines for the development of complex interventions [20], and has 132 
been described previously [15] (see Additional file 2 for TIDieR checklist for intervention 133 
description). In brief, intervention content was developed by the project team and was 134 
informed by prior research on multidimensional physical activity and feedback in at-risk 135 
patient populations in primary care [12, 14]. We showed that at-risk groups were confident in 136 
using the technology and found feedback to be understandable and motivating. However, 137 
consistent with other qualitative work in at-risk patients [21] it was identified that health 138 
trainer support would be useful for sustaining motivation and engagement. 139 
 140 
Behaviour change techniques common with successful lifestyle interventions were targeted 141 
by both the web-based app and the trainers [7]. The most prominent behavioural strategies 142 
in the web-based app (corresponding to an established taxonomy) [22], included feedback 143 
on behaviour (2.2), self-monitoring of physical activity behaviour (2.3), setting and reviewing 144 
goals in the context of target dimensions (1.1 & 1.5) and visualising the discrepancy 145 
between one’s behaviour and the health target (1.6). Health trainers were able to tailor the 146 
content of their discussions but were encouraged to discuss action planning/implementation 147 
intentions of physical activity (1.4), the health consequences of physical activity (5.1), 148 
instruction on how to perform specific physical activities (4.1) and building self-belief (15.1 & 149 
15.3).  150 
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 151 
Recent research has shown that the use of multiple co-acting behaviour change techniques 152 
are required to promote motivationally adaptive healthcare environments [23, 24]. Thus, and 153 
in addition to the use of behaviour change techniques, a number of theoretically-informed 154 
intervention components based on self-determination theory were applied [25]. Within self-155 
determination theory, healthcare exchanges that are supportive of an individual’s basic 156 
psychological needs for autonomy (i.e., need to feel that one’s behaviours are self-endorsed 157 
and volitional), competence (i.e., the need to feel effective and experience mastery in ones 158 
actions) and relatedness (i.e., the need to feel connected and cared for) are held to facilitate 159 
greater autonomous motivation and subsequently improved performance and increased 160 
maintenance of a given behaviour [26, 27]. The MiPACT intervention sought to support 161 
autonomy through the provision of behavioural choice inherent in the multidimensional 162 
physical activity profiles and via the trainer discussions wherein the users’ perspective of 163 
their current behaviour was explored, the use of a meaningful rationale, and encouragement 164 
to explore new enjoyable activities. Competence was targeted via the clear, visual feedback 165 
and self-monitoring of behaviour, and through the trainer supporting individuals in 166 
overcoming barriers to change, setting realistic goals and action plans, and by means of the 167 
provision of constructive verbal feedback and encouragement when talking through the 168 
visual data. Trainers were also encouraged to show empathy, acknowledge participant 169 
feelings, and build a collaborative relationship to support the need for relatedness. 170 
 171 
All participants (including the control group) attended an initial 20-minute meeting with a 172 
health trainer and received standardised information (including print-based materials and 173 
links to internet-based resources) regarding type II diabetes and cardiovascular disease, the 174 
potential benefits of physical activity on ‘risk’ reduction, current physical activity guidelines, 175 
ideas about getting more physically active, and included signposting to local opportunities. 176 
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Content was consistent with other print and internet-based resources such as NHS Choices 177 
(www.nhs.uk/livewell). Hence, the trial assessed effectiveness over-and-above existing 178 
‘usual care’ alternatives. Control group participants received no further study intervention. 179 
 180 
The MIPACT intervention involved access to a sophisticated wearable activity monitor and a 181 
customised web-based app for 3 months. The physical activity monitor was a multisensor 182 
device that estimates energy expenditure (BodyMedia Core). Participants were encouraged 183 
to wear activity monitors as much as possible and to regularly access the platform during the 184 
intervention. Personalised physical activity feedback could be accessed by participants 185 
using the web-based app at any point over a given 24-hour period. Participants were also 186 
offered a further four (20-30 minute) in-person health trainer sessions at approximately 2, 4, 187 
8 and 12 weeks. Health trainers included 5 registered (e.g. dieticians) and non-registered 188 
healthcare professionals (e.g. health trainers) recruited from the local community with 189 
experience as physical activity or lifestyle advisors, in order to make the study as pragmatic 190 
and generalisable as possible to routine healthcare practice. Health trainers were provided 191 
written materials and 2-days of intervention delivery training and focusing on using an 192 
autonomy supportive style [15]. 193 
 194 
We included a range of strategies outlined by the National Institute of Health Behavior 195 
Change Consortium to reinforce intervention fidelity [28]. We (1) developed and 196 
implemented standardised training of intervention providers (2) trained more MIPACT 197 
trainers than needed to protect against dropout or illness (3) recorded a selection of 198 
consultation meetings for a sample of sessions per intervention provider (4) implemented 199 
fidelity checklists, and (5) provided formative feedback to health trainers. Engagement of 200 
participants with the use of activity monitors and the web-based app was assessed by the 201 
number of monitor wear days across the intervention, the number of days that monitor data 202 
were uploaded to the web-based app, and the total number of trainer sessions attended. 203 
 204 
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Activity monitor data were used to generate personal visual feedback and to enable remote 205 
self-monitoring through the app. Multidimensional physical activity data were depicted in a 206 
simple wheel and bar chart format using traffic light color-coding as an index of attainment 207 
[15]. Each participant’s profile captured five different dimensions: (1) total energy 208 
expenditure, (2) minutes engaged in moderate-to-vigorous physical activity (MVPA) (3) time 209 
engaged in MVPA in ≥10-minute bouts (4) time engaged in vigorous physical activity in ≥10-210 
minute bouts, and (5) sedentary time as a proportion of the waking day. The app included 211 
feedback on time spent and energy expended at different physical activity intensities 212 
(sedentary, light, moderate, vigorous and very vigorous), expressed in metabolic equivalents 213 
(METs). In order to convert energy expenditure to METs, we used age-specific equations for 214 
Basal Energy Expenditure [29]. This was used to determine the amount of time engaged in 215 
sedentary behaviour (<1.8 METs), light intensity physical activity (1.8 – 3 METs), MVPA (≥3 216 
METs) and vigorous intensity physical activity (≥6 METs). These data were presented as 24-217 
hour line graphs and daily/weekly summary charts using a ‘heat’ colour palette [15]. The app 218 
also offered reviewing and planning components, and functionality for tagging different 219 
behaviours as part of the self-monitoring process [15]. 220 
 221 
The aim of the first health trainer session was to explain the multidimensional nature of 222 
physical activity and physical activity intensity thresholds, discuss which personal behaviours 223 
contributed to each dimension and discuss acceptable and available options to increase 224 
daily physical activity. Participants were encouraged to engage in new and enjoyable 225 
activities. A focus of the second session was to review progress and to discuss aspects that 226 
participants would consider changing and to set a SMART (Specific, Measurable, Attainable, 227 
Realistic, and Time-bound) goal. Subsequent sessions involved reviewing physical activity 228 
behaviour(s) and supporting efforts to be more active and included continued support in 229 
refining goals and action plans. The process was led by the participant (i.e. “self-regulated”) 230 
and was highly individualised. 231 
 232 
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Outcome measures 233 
All participants were assessed at baseline and followed up at 3 and 12 months within clinic. 234 
The primary outcome was device-based assessment of physical activity at 12 months. The 235 
device used to collect physical activity energy expenditure was a research-grade multisensor 236 
instrument worn on the upper arm (BodyMedia Core, BodyMedia Inc., Pittsburgh, PA) that 237 
has been used in research studies and has excellent reported accuracy [30, 31]. Underlying 238 
raw minute-by-minute estimates of energy expenditure were extracted in order to undertake 239 
the necessary data processing to then extract the specific physical activity metrics needed 240 
for our analysis (SenseWear® Pro 8.0, algorithm v5.2). Weekly physical activity energy 241 
expenditure records were exported to Excel for processing. Data were considered valid if the 242 
participant wore the device for ≥6 days in which 80% or more data were captured within a 243 
given 24-hour period. Missing data were assigned estimated energy expenditure equivalent 244 
to basal metabolic rate (Schofield et al., 1985). Physical Activity Level (PAL) was determined 245 
as the product of Total Energy Expenditure/Basal Metabolic Rate. Multiple other key 246 
physical activity dimensions were calculated, including: overall energy expenditure 247 
(expressed as PAL); accumulated minutes engaged in MVPA (≥3 METs) and in ≥10-minute 248 
bouts; time engaged in vigorous intensity physical activity (≥6 METs) in ≥10-minute bouts, 249 
and sedentary time (<1.8 METs), where one MET represents resting metabolic rate. 250 
 251 
As per study protocol [15], to explore if any change in physical activity is meaningful in terms 252 
of health risk, we included secondary outcomes for the change between baseline and 12 253 
months in body mass, body mass index, waist circumference, fat mass, systolic and diastolic 254 
blood pressure, glucose control (glucose and insulin), lipids (total cholesterol, high-density 255 
and low-density lipoprotein cholesterol, triglycerides), and C-reactive protein. Anthropometric 256 
measurements and blood samples were taken by a research nurse in clinic, while body 257 
composition was estimated using dual energy X-ray absorptiometry. Risk scores were based 258 
on QRISK and QDiabetes prediction algorithms [16, 17] using clinical data. Health status 259 
was assessed using the Euroqol 5-D visual analogue scale (EQ5-D) [32]. A full process 260 
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evaluation for MIPACT, including self-reported psychosocial variables, will be published 261 
separately. 262 
 263 
Statistical analysis 264 
For a targeted difference in PAL of 0.07 and an SD of 0.18,[15] 2-sided P=0.05, 90% power, 265 
an assumed correlation between baseline and follow-up of r = 0.7, and a 2:1 allocation ratio, 266 
the required sample size (allowing for 25% attrition) was 144 in the intervention group and 267 
72 in the control (ANCOVA model) [33]. In an as-randomised analysis, we estimated the 268 
mean difference in 12-month outcome between arms. We applied a linear mixed model with 269 
restricted maximum likelihood and an identity covariance structure. All minimization factors 270 
and the baseline value of the outcome were included as fixed effects, plus a random slope 271 
for group allowing different response variances. The same analysis was applied to all 272 
physical activity dimensions, with no adjustment for multiplicity [34].  273 
 274 
Our definition of the minimum clinically important difference (MCID) for MVPA was based on 275 
a prospective study of adults at risk of type 2 diabetes mellitus, wherefrom we can derive 276 
that the mean increase in MVPA time per day associated with a clinical meaningful 10% 277 
relative risk reduction in all-cause mortality was approximately 20% [35]. In the current 278 
study, 20% of the baseline mean equated to around 30 min/day and 20 min/day, 279 
respectively, for MVPA and for MVPA in 10-min bouts. The MCID for vigorous physical 280 
activity in 10-min bouts was set at half of that for MVPA (10 min/day), as there is no robust 281 
clinical anchor. The MCID for PAL was defined as 0.07, as detailed in our protocol paper 282 
[15], and for sedentary time as 1 hour per day, as there is no robust clinical anchor 283 
independent of MVPA. 284 
 285 
Model specification was evaluated by visual inspection of residuals plots. Mean intervention 286 
effects are presented with 2-sided 95% confidence intervals, providing a range of effect 287 
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sizes compatible with the data and model. A zero effect ± the MCID defines a region of 288 
practical equivalence. The disposition of the confidence interval to this region may be used 289 
to statistically rule out substantial beneficial (favouring intervention) or harmful (favouring 290 
control) effects, equivalent to two 1-sided tests each at the 0.025 level [36]. In short, if the 291 
entire confidence interval lies within the region of zero ± the MCID then the groups may be 292 
considered practically equivalent for that outcome. The same analyses were repeated for the 293 
3-month physical activity outcomes and for the health-related outcomes at 3 and 12 months, 294 
and are presented for description only.  295 
 296 
With missing data on the dependent variable only, maximum likelihood reduces to a 297 
complete case analysis under a plausible missing at random assumption, and therefore 298 
cases with missing outcome data (c. 10%) were deleted. Finally, in our trial protocol we 299 
stated that we would explore treatment effect heterogeneity. However, when the mean 300 
intervention effect is close to zero, the plausibility of the implicit assumption that a proportion 301 
of participants would get substantially worse with the intervention is questionable. Therefore, 302 
we omitted the planned analysis of intervention response heterogeneity. All analyses were 303 
performed using Stata software (StataCorp, 2017. Stata Statistical Software: Release 15, 304 
College Station, TX, USA: StataCorp LP). 305 
 306 
Patient and public involvement 307 
The public were involved in this study in several ways. Draft graphics and visualisations for 308 
presenting multidimensional physical activity data (initially developed alongside designers) 309 
were refined based upon feedback from in-depth qualitative interviews in at-risk patients 310 
(n=29) and healthcare practitioners (n=15) from two regions in the United Kingdom (Bath 311 
and North East Somerset and Wiltshire). Overall, patients preferred simple messages rather 312 
than more complex or abstract visualisations. Also, while technology-enabled physical 313 
activity feedback was found to be informative, understandable and motivating, it was the 314 
view of patients and practitioners that supplementary in-person guidance may further 315 
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support behaviour change and this informed the decision to include one-to-one health trainer 316 
sessions in MIPACT [12]. Participants were provided with their results and were invited to 317 
attend focus groups at the end of the study to learn more about their experiences of the trial. 318 
 319 
RESULTS 320 
Participants 321 
The flow of participants from recruitment through to final assessment at 12 months is shown 322 
in Figure 1. Participant characteristics were similar between groups at baseline (Table 1).  323 
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Table 1. Characteristics of Study Participantsa,b 324 
Variable Total (n=204) Control (n=70) Intervention (n=134) 
Age (years) 64 (6) 63 (6) 64 (6) 
Male sex 131 (64) 45 (64) 86 (64)  
Ethnicity: White British 180 (88) 63 (90) 117 (87) 
Marital Status: Married 150 (74) 54 (77) 96 (72) 
Employment status    
     In full or part-time employment 85 (42) 31 (44) 54 (40) 
     Retired 116 (57) 38 (54) 78 (58) 
Area deprivation (IMD score) 7.6 (2.3) 7.7 (2.4) 7.6 (2.3) 
Education levels    
     Up to age 16 or less 63 (31) 18 (26) 45 (34) 
     Up to age 18 60 (29) 26 (37) 34 (25) 
     Undergraduate / higher degree 81 (40) 26 (37) 55 (41) 
Current smoker 20 (10) 10 (14) 10 (7) 
Body mass (kg) 85.2 (14.3) 86.6 (14.1) 84.5 (14.4) 
Body mass index (kg/m2) 29.1 (4.4) 29.4 (4.3) 28.9 (4.4) 
DEXA    
     Total body fat (%) 33.4 (8.1) 33.0 (8.5) 33.5 (7.9) 
     Visceral body fat (cm2) 188 (60) 195 (66) 184 (57) 
     Fat mass index (kg/m2) 9.7 (3.5) 9.7 (3.6) 9.7 (3.4) 
Waist circumference (cm) 100.3 (10.6) 101.2 (10.6) 99.8 (10.5) 
Blood pressure (mm Hg)    
     Systolic  132 (16) 132 (17) 132 (16) 
     Diastolic 84 (9) 83 (10) 84 (9) 
Fasting glucose (mmol/L) 5.1 (0.5) 5.1 (0.5) 5.1 (0.4) 
Fasting insulin (mU/L) median (IQR) 54.8 (41.1, 82.2) 58.9 (37.5, 84.1) 51.4 (42.4, 80.4) 
HOMA-IR median (IQR) 1.8 (1.3, 2.7) 1.9 (1.2, 2.8)) 1.7 (1.3, 2.6) 
Cholesterol (mmol/L)    
     Total cholesterol 5.8 (1.0) 5.7 (0.9) 5.9 (1.1) 
     Low-density lipoprotein cholesterol 3.6 (0.9) 3.5 (0.9) 3.7 (1.0) 
     High-density lipoprotein cholesterol 1.6 (0.4) 1.5 (0.4) 1.6 (0.5) 
Triglycerides (mmol/L) 1.4 (0.6) 1.4 (0.7) 1.4 (0.6) 
QRISK2: 10-year risk (%) 14.4 (6.3) 13.8 (6.2) 14.8 (6.4) 
QDiabetes: 10-year risk (%) 13.5 (9.4) 12.9 (6.9) 13.9 (10.5) 
Physical Activity    
     Sedentary time (min/day) 662 (111) 651 (117) 668 (107) 
     MVPA (min/day) 149 (57) 157 (60) 146 (56) 
     MVPA10 (min/day) 96 (47) 103 (52) 92 (44) 
     Vigorous10 (min/day) median (IQR) 3 (0, 9) 3 (0, 11) 3 (0, 8) 
     PAL  1.68 (0.16) 1.70 (0.16) 1.67 (0.16) 
EQ5-D VAS 72 (16) 73 (16) 71 (15) 
Abbreviations: IMD, Index of multiple deprivation; DEXA, Dual-energy X-ray absorptiometry; HOMA-325 
IR, Homeostatic model assessment – Insulin resistance; PAL, Physical activity level; EQ5-D VAS, 326 
Euroqol 5-D visual analogue scale (health-related quality of life).  327 
a Data are expressed as mean (SD) for continuous data, or N (%) for categorical data. Highly skewed 328 
continuous data are presented as median (interquartile range; IQR).  329 
b N=186 for DEXA; N=204 for all other variables.330 
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 331 
Effect of the intervention on physical activity outcomes 332 
Adjusted means for device-measured physical activity at 12 months (primary endpoint) and 333 
3 months are presented in Table 2.  For the primary timepoint at 12 months, the point 334 
estimates and lower and upper confidence limits for the intervention effect (vs. control) for all 335 
dimensions were all trivial in relation to the smallest effect sizes of interest. For all physical 336 
activity dimensions the confidence interval is entirely within the equivalence region (defined 337 
by ± the MCID), indicating that clinically meaningful mean population effects (as defined) 338 
may be ruled out at the given level of error control.  339 
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Table 2. Adjusted means for device-based physical activity outcomes at 3 months and 340 
12 monthsa,b (All outcomes in minutes/day unless stated) 341 
 342 
Abbreviations: MVPA, moderate-to-vigorous physical activity; MVPA10, moderate-to-vigorous physical 343 
activity in bouts of at least 10 minutes; Vigorous10, Vigorous physical activity in bouts of at least 10 344 
minutes; PAL, Physical Activity Level (ratio of total daily energy expenditure to resting metabolic rate). 345 
a Adjusted for all minimization factors and baseline value of the outcome variable. 346 
b N=183 for sedentary time at 3 months; N=184 for all other variables at 3 and 12 months. 347 
c Confidence interval verified using a bias-corrected and accelerated bootstrap with 2000 replication. 348 
 349 
Effect of the intervention on health outcomes 350 
Adjusted means for health-related outcomes are shown in Table 3. These data are provided 351 
for descriptive/exploratory purposes only.  352 
Variables Intervention Control Difference (95% CI) 
Sedentary    
   3 months 651.1 632.5 18.6 (-8.9 to 46.2) 
   12 months 667.1 657.1 10.0 (-19.3 to 39.3) 
MVPA    
   3 months 163.4 174.8 -11.4 (-27.7 to 4.9) 
   12 months 161.9 163.0 -1.1 (-17.9 to 15.7) 
MVPA10    
   3 months 112.4 115.1 -2.7 (-17.2 to 11.9) 
   12 months 107.0 106.8 0.2 (-14.2 to 14.6) 
Vigorous10    
   3 months 9.8 8.1 1.7 (-1.6 to 4.1)c 
   12 months 8.1 6.3 1.8 (-0.8 to 4.2)c 
PAL    
   3 months 1.72 1.74 -0.02 (-0.07 to 0.03) 
   12 months 1.71 1.71 0.00 (-0.036 to 0.054) 
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Table 3. Adjusted means for health-related outcomes at 3 and 12-monthsa 353 
Variable N Intervention Control 
Difference (90% 
CI) 
Body mass (kg)     
     3 months 188 84.1 84.3 -0.2 (-1.0 to 0.5) 
     12 months 186 83.6 84.4 -0.8 (-1.8 to 0.2) 
Body mass index 
(kg/m2) 
    
     3 months 188 28.6 28.7 -0.1 (-0.3 to 0.1) 
     12 months 186 28.5 28.8 -0.3 (-0.6 to 0.04) 
Waist 
circumference 
(cm) 
    
     3 months 188 98.3 98.0 0.3 (-0.6 to 1.2) 
     12 months 186 99.2 99.0 0.2 (-1.2 to 1.5) 
Total body fat 
(%) 
    
     3 months 165 32.6 32.5 0.1 (-0.4 to 0.6) 
     12 months 166 32.4 32.7 -0.3 (-0.8 to 0.3) 
Visceral body fat 
(cm2) 
    
     3 months 165 180.4 183.1 -2.7 (-8.8 to 3.4) 
     12 months 166 186.9 193.1 -6.2 (-13.8 to 1.4) 
Fat mass index 
(kg/m2) 
    
     3 months 165 9.3 9.3 0.0 (-0.2 to 0.2) 
     12 months 166 9.3 9.5 -0.2 (-0.4 to 0.1) 
SBP (mmHg)     
     3 months 188 129 130 -1 (-5 to 3) 
     12 months 186 133 133 0 (-3 to 3) 
DBP (mmHg)     
     3 months 188 83 85 -2 (-4 to 0) 
     12 months 186 82 83 -1 (-3 to 1) 
Glucose 
(mmol/L) 
    
     3 months 188 5.1 5.1 0.0 (-0.1 to 0.1) 
     12 months 183 5.1 5.2 -0.1 (-0.2 to 0.0) 
Insulin (mU/L)b     
     3 months 183 65.8 68.3 -2.5 (-8.7 to 4.0) 
     12 months 181 72.2 71.7 0.5 (-7.9 to 9.6) 
HOMA-IRb     
    3 months 183 2.2 2.2 0.0 (-0.3 to 0.2) 
    12 months 177 2.4 2.4 0.0 (-0.4 to 0.3) 
Total cholesterol 
(mmol/L) 
    
     3 months 188 5.6 5.7 -0.1 (-0.2 to 0.1) 
     12 months 184 5.7 5.8 -0.1 (-0.3 to 0.05) 
LDL cholesterol 
(mmol/L) 
    
     3 months 188 3.4 3.4 0.0 (-0.2 to 0.2) 
     12 months 184 3.4 3.5 -0.1 (-0.2 to 0.1) 
HDL cholesterol 
(mmol/L) 
    
     3 months 188 1.6 1.6 0.0 (-0.06 to 
0.04)      12 months 184 1.6 1.6 0.0 (-0.1 to 0.03) 
Continued… 354 
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 355 
Abbreviations: SBP, Systolic blood pressure; DBP, Diastolic blood pressures; HOMA-IR, Homeostatic 356 
model assessment – Insulin resistance. LDL, Low density lipoprotein; HDL, High density lipoprotein; 357 
CRP, C-reactive protein; CVD, Cardiovascular disease; EQ5D, Health related quality of life. 358 
a Adjusted for all minimization factors and baseline value of the outcome variable. 359 
b Confidence interval verified using a bias-corrected and accelerated bootstrap with 2000 replications. 360 
 361 
Adherence and adverse events 362 
The dose and coverage of intervention delivery was high. Among those receiving the 363 
MIPACT intervention, the mean (SD) number of days that activity monitors were worn across 364 
the 3-month intervention period was 72 (25) days. Of these, the number of days regarded as 365 
complete (i.e. ≥80% data for a given 24-hour period) was 61 (26) days. On average, 366 
participants uploaded data to the platform on 24 (21) unique days. Of the 134 participants in 367 
the MIPACT intervention group, 121 (90%) attended ≥4 health trainer sessions, and 105 368 
(78%) attended all 5 training sessions. After excluding participants who dropped out from the 369 
study, 85% attended all sessions. One participant in the control group died due to reasons 370 
deemed unrelated to the study.  In total, there were only ten serious adverse events reported 371 
between the intervention and control groups: 7 (6%) of 120 and 3 (4%) of 84, respectively, 372 
and none were deemed related to participation in the study.  373 
Variable N Intervention Control 
Difference (90% 
CI) 
Triglycerides 
(mmol/L)b 
    
    3 months 188 1.4 1.5 
-0.1 (-0.25 to 
0.03) 
    12 months 184 1.4 1.5 -0.1 (-0.2 to 0.1) 
CRP (mg/l)b     
    3 months 186 2.5 3.3 -0.8 (-1.5 to -0.1) 
    12 months 183 3.2 3.1 0.1 (-0.7 to 0.9) 
CVD risk: 10-year 
risk (%)b 
    
    3 months 188 14.0 14.0 0.0 (-0.5 to 0.5) 
    12 months 186 15.0 14.9 0.1 (-0.5 to 0.7) 
Diabetes risk: 10-
year risk (%)b 
    
    3 months 188 12.8 13.0 -0.2 (-0.7 to 0.3) 
    12 months 186 12.9 13.6 -0.7 (-1.5 to 0.02) 
EQ-5D     
    3 months 184 77.4 74.3 3.1 (0.0 to 6.2) 
    12 months 186 75.7 72.4 3.3 (-1.4 to 8.2) 
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DISCUSSION 374 
In primary care patients at risk of chronic disease, we evaluated an intervention comprising 375 
personal technology-enabled feedback on multiple specific dimensions of physical activity 376 
combined with health trainer support. At 12-months follow-up, the intervention and control 377 
groups were statistically equivalent for all physical activity outcomes and sedentary time. 378 
Between participants there was considerable variation (or heterogeneity) across the multiple 379 
physical activity dimensions, with only 11 participants (5%) presenting at baseline with 380 
uniformly low physical activity across all dimensions. 381 
 382 
Comparison with other studies 383 
We developed a highly sophisticated system for providing personalised multidimensional 384 
physical activity feedback that was informed by patients and practitioners (MIPACT). This 385 
approach did not change physical activity in at risk patients recruited from primary care. 386 
MIPACT confirms that, even using the latest technology as part of a multicomponent 387 
intervention, it is hard to motivate people at risk of disease to change their physical activity 388 
behaviours. The MIPACT trial represents a first attempt to leverage technology to improve 389 
the depth and quality of feedback to at-risk patients about the multiple dimensions of 390 
physical activity that can play a role in disease prevention [10, 11, 14]. To date, physical 391 
activity feedback interventions have typically focused on just one aspect of physical activity 392 
behaviour (e.g. moderate physical activity). In a primary care setting, there is some evidence 393 
that personalised physical activity feedback on MVPA [37] or pedometer steps [38] as part of 394 
more intensive lifestyle interventions can lead to increases in physical activity. However, 395 
these effects were modest, and studies targeted patients with existing chronic disease. No 396 
prior randomised trial has examined the effects of providing personal feedback on multiple 397 
physical activity dimensions as part of a technology-enabled behavioural intervention in at-398 
risk patient populations. 399 
  400 
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Meaning of the study: possible explanations and implications 401 
There are several potential reasons for the lack of substantial intervention effects on 402 
physical activity outcomes, including explanations related to the novel multidimensional 403 
approach that was employed in MIPACT for the first time. We recruited patients based on 404 
the presence of a specific score in a predefined physical activity dimension (PAL <2.0), and 405 
thus participants could still score relatively highly for other physical activity dimensions. To 406 
illustrate this point, the majority of participants (58%) scored highly (green) for at least one 407 
physical activity dimension at baseline and only 11 participants (5%) had universally low 408 
physical activity across all dimensions (Figure 2). Thus, most participants would have 409 
received at least a partially positive message about some aspect of their physical activity 410 
behaviour from the online platform and during health trainer sessions. From a behaviour 411 
change standpoint, receiving positive feedback (even in just one dimension of physical 412 
activity) could reinforce the “appropriateness” of an individual’s existing behaviour and 413 
lessen the perceived need to change physical activity behaviour especially in areas that 414 
participants do not think match their lifestyle and their preferences [12, 13]. Clinical practice 415 
might consider focusing on priority populations with uniformly low physical activity across all 416 
dimensions. 417 
 418 
The lack of substantial intervention effects could also be explained by study inclusion based 419 
on absolute risk scores, which may be biased towards healthy older people. Disease-risk 420 
algorithms such as QRisk do not directly consider the impact of physical activity and 421 
estimated risk is heavily influenced by age [17]. To illustrate this point, a lean non-smoking 422 
64-year old man with no family history or risk factors for cardiovascular disease would have 423 
been eligible for MIPACT with a 10-year QRISK score of 13.9%. Thus, inclusion was heavily 424 
influenced by age-related absolute risk score, which is a poor proxy for lifestyle-related 425 
health outcomes. Indeed, in MIPACT, participants had a slightly higher mean PAL (1.68) 426 
than the UK median (1.63) [39, 40]. Thus, Health Check programmes with a focus on 427 
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prevention may need to avoid using absolute risk scores and consider targeting populations 428 
with higher relative risk. 429 
 430 
Strengths and limitations of this study 431 
The current study has several important strengths. We used a precise device-based 432 
measure of physical activity and achieved exceptional 24-hour, 7-day compliance (>98%) 433 
across all assessment periods. We adopted an innovative approach to try and avoid short-434 
term changes in physical activity during assessment periods by using sham activity monitors 435 
in the 1-month prior to follow-up [15]. Also, we adopted a pragmatic intention-to-treat (as 436 
randomised) analysis as well as an extended post-intervention follow-up assessment at 12 437 
months. Participant retention in the trial was high (91%) and did not differ substantially 438 
between study groups. The study also had a number of limitations. Participants came from a 439 
single UK region, were well educated, and exhibited limited ethnic and socioeconomic 440 
diversity. As such, our findings may not be generalisable to other cohorts and settings, 441 
although representativeness is not a prerequisite for a valid evaluation of relative efficacy/ 442 
effectiveness in a randomised trial [41].    443 
 444 
Conclusions 445 
In primary care patients at risk of cardiovascular disease and/or type II diabetes, a highly 446 
sophisticated digital monitoring system along with support from a health trainer (MIPACT) 447 
did not increase mean physical activity levels compared to usual care. MIPACT shows that 448 
physical activity is hard to change in patients recruited from primary care in the longer term, 449 
even with highly sophisticated digital technologies. The multidimensional individual-level 450 
characterisation revealed enormous heterogeneity in physical activity in primary care 451 
patients, and only a small proportion of patients had low physical activity across all 452 
dimensions. Practitioners may need to screen for inactivity across multiple outcomes/metrics 453 
rather than rely on disease-risk algorithms that are heavily influenced by age.  454 
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Figure 1. Flow of participants through the MIPACT study 455 
MIPACT, Multidimensional Individualized Physical ACTivity. 456 
 457 
Figure 2. Multidimensional Physical Activity Profiles of Participants at Baseline 458 
PART A: Unadjusted physical activity data of participants across multiple specific 459 
dimensions of physical activity at baseline PART B: Proportion of participants scoring highly 460 
for one or more dimensions of physical activity at baseline 461 
PAL, Physical Activity Level (ratio of total daily energy expenditure to resting metabolic rate); 462 
SED, Sedentary; MVPA, moderate-to-vigorous physical activity; MVPA10, moderate-to-463 
vigorous physical activity in bouts of at least 10 minutes; VIG10, Vigorous physical activity in 464 
bouts of at least 10 minutes. 465 
In this simple iteration, and as described [15], green/red indicate achievement/failure to 466 
achieve each threshold, with amber indicating that values are near to achieving the 467 
threshold. 468 
 469 
Abbreviations 470 
MIPACT: Multidimensional Individualised Physical ACTivity; NHS: National Health Service; 471 
PAL: Physical Activity Level; MVPA: Moderate-to-Vigorous Physical Activity; METs: 472 
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